Centre for Drug Development news archive

Explore our archive of news, features and press releases from us and our partners, including new collaborations, licensing, clinical trial milestones and results.

View our most recent updates

2024

CDD and KisoJi partner to advance first naked TROP2 antibody into the clinic

First patient dosed in CDD first in human trial of new immunotherapy

Cancer Research UK and NovalGen collaborate to advance T-cell engager into the clinic

Results of our trial of Bicycle Therapeutics' first in class Bicycle® Toxin Conjugate

Trial of Nxera's cancer immunotherapy at the European Society for Medical Oncology (ESMO) congress

Let’s make a real difference in cancer: sitting down with Lars Erwig

First patient dosed in CDD Phase 2 trial of new pancreatic drug ginisortamab

Beyond Borders: going global with clinical trials

CDD and the Norwegian Cancer Society partner to bring more novel treatments into the clinic

First patient dosed in CDD Phase 1 trial of Aleta Biotherapeutics' CAR T cell engager

Cancer Research UK and Stitch strengthen their partnership, collaborating on two new studies

Director of our Formulation Unit awarded OBE 

2023

Cancer Research UK appoints new director to lead its Centre for Drug Development  

A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) (SPIKE-1) 

Cancer Research UK and Guardant Health launch collaboration to advance cancer research and clinical development activities

Cancer Research UK and the KWF Dutch Cancer Society enter partnership to bring multiple drugs into clinical development 

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023 

Patients with rare cancers given hope by UK-led ‘drug-match’ trial 

Sosei Heptares and Cancer Research UK announce the dosing of the first patient in a Phase 1/2a trial with cancer immunotherapy drug HTL0039732 

New class of antibody drug shows promise for cancer patients 

Topline Phase 1 study results with VAC2 for the treatment of advanced non-small cell lung cancer 

Cancer Research UK joins European precision cancer medicine trial consortium 

Study Details | Phase I Study of MOv18 IgE

Cancer Research UK signs multi-project collaboration with UCB to advance oncology antibody candidates 

Hummingbird Bioscience exercises its option to license clinical trial results from Cancer Research UK

2022

Novartis joins Cancer Research UK trial for rare cancers 

App for patients on a clinical trial piloted by Cancer Research UK 

Precision medicine trial opens for rare adult and paediatric cancers

Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001

Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials

Cancer Research UK reveals innovation engine underpinned by £400m portfolio of cutting-edge discovery science

Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs 

Study Details | A Phase I Trial of AZD3965 in Patients With Advanced Cancer

Cancer Research UK and Teon Therapeutics announce first patient dosed in clinical trial for hard-to-treat solid cancers

World Cancer Day: Celebrating Life-Saving Research 

Tailored Patient Involvement in Clinical Trials

Cancer Research UK dose first patient in phase I/IIa trial of lung cancer immunotherapy vaccine

2021

Cancer researchers across the UK join forces to find drugs for rare cancers

Cancer Research UK announces first patient dosed in trial for hard-to-treat cancers

Aleta Biotherapeutics and Cancer Research UK collaborate to advance blood cancer therapy into the clinic

Funding bodies should foster partnerships between industry and academia

2020

Teon Therapeutics Announces Approval for Collaboration with Cancer Research UK

Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma

Lineage Cell Therapeutics Announces Early Exercise of Option with Cancer Research UK for Immuno-Oncology Cell Therapy Program

Bicycle Therapeutics Announces First Patient Dosed in Phase IIa Trial of Bicycle® Toxin Conjugate BT1718

2019

First-in-human trial for new lung cancer immunotherapy

BioInvent signs manufacturing agreement with Cancer Research UK expected to generate approximately SEK 30 million (~$3 million)

A Medidata and Cancer Research UK Podcast | Patient Centricity Within Clinical Trials